drugset / Trial / NCT05244980
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
Timeline
- Start
- 2022-02-01
- Primary completion
- 2022-11-15
- Completion
- 2023-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TDM-105795 | Unknown | 0.0025 % | Topical |
| Subject | TDM-105795 | Unknown | 0.005 % | Topical |
| Subject | TDM-105795 | Unknown | 0.01 % | Topical |
| Subject | TDM-105795 | Unknown | 0.02 % | Topical |